Financial Analysis: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM)

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Volatility and Risk

Kiniksa Pharmaceuticals International has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Valuation & Earnings

This table compares Kiniksa Pharmaceuticals International and Mirum Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56 million	9.05	$59.01 million	$0.97	81.02
Mirum Pharmaceuticals	$521.31 million	9.98	-$23.36 million	($14.55)	-5.51

Kiniksa Pharmaceuticals International has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

53.9% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Kiniksa Pharmaceuticals International and Mirum Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0	1	8	0	2.89
Mirum Pharmaceuticals	1	0	13	1	2.93

Kiniksa Pharmaceuticals International presently has a consensus target price of $93.14, suggesting a potential upside of 18.52%. Mirum Pharmaceuticals has a consensus target price of $147.88, suggesting a potential upside of 84.52%. Given Mirum Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Kiniksa Pharmaceuticals International.

Profitability

This table compares Kiniksa Pharmaceuticals International and Mirum Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Summary

Kiniksa Pharmaceuticals International beats Mirum Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.